Conditions: Acute Myeloid Leukemia
Keywords: Acute myeloid leukemia WT1
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the safety of OCV-501 in patients with AML who completed the Study 311-10-001 and were judged that there was no relapse by any inspections in the end of the study.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: OCV-501
Intervention descriptions: intervention 1: 1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.
2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose.

Protocol document: